Press release
Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Polycystic Kidney Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Polycystic Kidney Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Polycystic Kidney Disease Pipeline Report
* In June 2025, Biogen announced a Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Patients will be enrolled in disease specific cohorts within the trial, and effectiveness of bardoxolone methyl in treating CKD will be assessed separately by cohort for each rare CKD.
* DelveInsight's Polycystic Kidney Disease Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Polycystic Kidney Disease treatment.
* The leading Polycystic Kidney Disease Companies such as Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc . and others.
* Promising Polycystic Kidney Disease Pipeline Therapies such as Rapamune, Lisinopril, Telmisartan, Empagliflozin 10 MG, Everolimus, Bosutinib, Tolvaptan MR and others.
Stay ahead with the most recent pipeline outlook for Polycystic Kidney Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Polycystic Kidney Disease Treatment Drugs [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Polycystic Kidney Disease Emerging Drugs Profile
* Tamibarotene: Rege Nephro Co., Ltd.
Tamibarotene, developed by Rege Nephro Co., Ltd., is a retinoic acid receptor (RAR) agonist currently undergoing clinical trials for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This drug, also known by its investigational code RN-014, is designed to inhibit cyst formation and improve renal function in patients suffering from this hereditary condition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Autosomal dominant polycystic kidney disease (ADPKD).
* RGLS8429: Regulus Therapeutics Inc.
RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown data in preclinical models, where improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound, RGLS4326. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Polycystic Kidney Disease.
* AL1311: AceLink Therapeutics, Inc.
AL1311 is a highly potent NRF2 activator that is being developed for Autosomal Dominant Polycystic Kidney disease (ADPKD). AL1311 is different from other electrophilic and reactive NRF2 activators because it works by disrupting the protein-protein interaction between NRF2 and its regulatory protein Keap1. Non-reactive NRF2 activators have the potential to have better specificity for NRF2 activation and therefore a better safety profile. Currently, the drug is in Preclinical stage of development for the treatment of Polycystic Kidney Disease.
The Polycystic Kidney Disease Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Polycystic Kidney Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycystic Kidney Disease Treatment.
* Polycystic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycystic Kidney Disease market
Explore groundbreaking therapies and clinical trials in the Polycystic Kidney Disease Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Drugs for Polycystic Kidney Disease [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Polycystic Kidney Disease Companies
Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc . and others.
Polycystic Kidney Diseases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Polycystic Kidney Disease Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Polycystic Kidney Disease Treatment. Learn about new drugs of Polycystic Kidney Disease, pipeline developments, and key companies with DelveInsight's expert analysis @ Polycystic Kidney Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Polycystic Kidney Disease Pipeline Report
* Coverage- Global
* Polycystic Kidney Disease Companies- Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc . and others.
* Polycystic Kidney Disease Pipeline Therapies- Rapamune, Lisinopril, Telmisartan, Empagliflozin 10 MG, Everolimus, Bosutinib, Tolvaptan MR and others.
* Polycystic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Polycystic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Polycystic Kidney Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Polycystic Kidney Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Polycystic Kidney Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Polycystic Kidney Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tamibarotene: Rege Nephro Co., Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RGLS8429: Regulus Therapeutics Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AL1311: AceLink Therapeutics, Inc.
* Inactive Products
* Polycystic Kidney Disease Key Companies
* Polycystic Kidney Disease Key Products
* Polycystic Kidney Disease- Unmet Needs
* Polycystic Kidney Disease- Market Drivers and Barriers
* Polycystic Kidney Disease- Future Perspectives and Conclusion
* Polycystic Kidney Disease Analyst Views
* Polycystic Kidney Disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polycystic-kidney-disease-pipeline-appears-robust-with-8-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polycystic-kidney-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4060406 • Views: …
More Releases from ABNewswire
Two-Time Emmy Award Winner Willa Brigham Announces New Book - Swatting Of The Fl …
Willa Brigham, the two-time Emmy Award-winning host of the beloved children's show Smart Start Kids , recently announced the publication of her first book of poetry titled, Swatting of the Fly . Known for her infectious energy and uplifting spirit, Willa brings that same warmth and wisdom to her latest work, set to release soon on Amazon.
Swatting of the Fly is a lively, emotional, and joyful collection of poems for…
Draft Products Revolutionizes UK Home Bars with Exclusive European Craft Beer an …
Leading importer brings authentic German and French craft brewing expertise directly to British beer enthusiasts' homes
LONDON, UK - June 16, 2025 - Draft Products, the UK's premier destination for European craft beer and home bar solutions, announces its continued expansion as the definitive source for authentic continental brewing experiences. Specializing in exclusive 5-liter beer keg systems and premium European craft imports, the company is transforming how British consumers experience draught…
Pompe Disease Market Set for Robust Growth Through 2034, Driven by Breakthrough …
The Pompe disease treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Sanofi, Genzyme, Amicus Therapeutics, GeneCradle Therapeutics, Astellas Gene Therapies, Spark Therapeutics, Aro Biotherapeutics, Maze Therapeutics, Valerion Therapeutics, Actus Therapeutics, Roche, and Lacerta Therapeutics, among others.
DelveInsight's "Pompe Disease Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/pompe-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the Pompe disease treatment…
PD-L1 Inhibitors Market Insight, Epidemiology, and Market Forecast - 2034 | Says …
PD-L1 inhibitors have become a vital part of modern cancer therapy by blocking the PD-1/PD-L1 pathway, which tumors use to evade immune detection. By restoring T-cell function, these therapies boost the body's ability to fight cancer. They have shown significant clinical benefit, including durable responses and improved survival, in several cancers such as NSCLC, TNBC, renal cell carcinoma, urothelial carcinoma, and head and neck squamous cell carcinoma.
DelveInsight's "PD-L1 Inhibitors Market…
More Releases for Polycystic
Polycystic Kidney Disease Treatment Comprehensive Analysis and Future Estimation …
According to Fact.MR, Insights of Polycystic Kidney Disease Treatment is a specialized and in-depth study of the industry with a special focus on the Key Trends of Polycystic Kidney Disease Treatment as a Service. The report aims to provide an overview with detailed segmentation by type, application, end use and geography. The global is expected to witness high growth during the forecast period.
A survey offers detailed analysis on key growth…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Polycystic Ovarian Syndrome - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Polycystic Ovarian Syndrome - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms…
Polycystic kidney disease Pharmaceutical and Healthcare Pipeline Review H2
Summary
Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2017, provides comprehensive information on…
Polycystic Ovary Syndrome Treatment Market Estimated to Flourish by 2024
Growth of the global polycystic ovary syndrome drugs market is mainly driven by increasing prevalence of the disease and a growing awareness among the patient population. Increasing purchasing power among people and rising awareness of PCOS are factors expected to drive growth of the global PCOS drugs market. The need for effective management of diseases associated with PCOS such as hirsutism, obesity, and infertility is likely to boost the demand…
